



PUBLIC HEALTH NOTES

JANUARY 2021 VOLUME 3, ISSUE 1

SHINGRIX: CONNECTING THE DOTS

HIGHLIGHTS

EFFICACY IN THE 4 YEARS POST IMMUNIZATION REMAIN CONSISTENT AND ABOVE 90% IN ALL AGE GROUPS WITH SLOWER WANING IMMUNITY.

.....

SHINGRIX IS A TWO DOSE INTRAMUSCULAR NON-LIVE RECOMBINANT VACCINE ADMINISTERED 2 TO 6 MONTHS APART.

.....

RE-IMMUNIZATION RISKS AND BENEFITS WITH SHINGRIX SHOULD BE DISCUSSED WITH THE HEALTH CARE PROVIDER.



Transition to Publicly Funded Shingrix Vaccine

Eligibility Criteria for the publicly funded Shingrix vaccine:

- Ontario seniors age 65 to 70 years (i.e., from the 65th birthday to the day prior to the 71th birthday)
- Patients who have not received publicly funded Zostavax.

Patients who are outside the eligibility criteria must privately purchase the 2 doses through their health care provider.

Current evidence and expert recommendations from NACI indicate that Shingrix is more effective for preventing herpes zoster infection and post-herpetic neuralgia.

To order Shingrix- visit www.rcdhu.com

For Professionals/ Health Care/Immunization to find Shingles Vaccine Order Form.



PUBLIC HEALTH NOTES

JANUARY 2021 VOLUME 3, ISSUE 1

FluMist® Quadrivalent (Live, Intranasal)

Publicly funded flu vaccine for 2 to 59 years of age



Due to increased demands of flu vaccine this season the Ministry of Health has secured FluMist® doses.

Current evidence does not provide preference of one administration method verses another pertaining to the 4-strain vaccines (injectable QIV verses Q-LAIV nasal spray).

INTERESTING INFORMATION:

- individuals with nasal congestion which would impede the delivery of the vaccine should delay vaccination until congestion is reduced
- egg allergy is not a contraindication
- individuals who receive the FluMist® spray should avoid close contact with individuals with severe immune compromising conditions for at least 2 weeks
- live attenuated vaccine virus can be shed from nose after administration
- breastfeeding mothers can receive FluMist® providing they do not have any other contraindications

WHO SHOULD NOT RECEIVE FLUMIST®:

- children younger than 24 months of age
- children <5 years of age with recurrent wheezing and any person with asthma may be at increased risk of wheezing post-administration
- anyone who had a serious reaction (anaphylaxis) following a previous dose of influenza vaccine
- anyone who developed Guillain-Barre Syndrome (GBS) within 6 months of previous influenza vaccination
- people with weakened immune system due to disease or medical treatment
- children less than 18 years of age who are on long-term aspirin-containing therapy
- individuals taking antivirals against influenza
- pregnant women

Be sure to check expiry date as current supply is expiring in February

COVID-19 PRECAUTIONS:







- Gloves, mask and eye protection are recommended when administering intranasal influenza due to increased likelihood of contact with mucous membranes and bodily fluids.
- Airborne precautions are not necessary for administration purposes.
- Individuals with acute respiratory infection, even minor symptoms such as sore throat or runny nose, should defer immunization until 10 days from onset of symptoms OR they have recovered.




PUBLIC HEALTH NOTES

JANUARY 2021 VOLUME 3, ISSUE 1

FluMist®

<p>1</p>  <p>Check expiration date. Product must be used before the date on sprayer label.</p>	<p>2</p>  <p>Remove rubber tip protector. Do not remove dose-divider clip at the other end of the sprayer.</p>	<p>3</p>  <p>With the patient in an upright position, place the tip just inside the nostril to ensure the vaccine is delivered into the nose.</p>
<p>4</p>  <p>With a single motion, depress plunger as rapidly as possible until the dose-divider clip prevents you from going further.</p>	<p>5</p>  <p>Pinch and remove the dose-divider clip from plunger.</p>	<p>6</p>  <p>Place the tip just inside the other nostril and with a single motion, depress plunger as rapidly as possible to deliver remaining vaccine.</p>

 **DO NOT INJECT. DO NOT USE A NEEDLE.**

Note: Active inhalation (i.e., sniffing) is not required by the patient during vaccine administration.

Resources

- [Ministry of Health: Health Care Provider Qs & As: FluMist® Quadrivalent](#)
- [National Advisory Committee on Immunization \(NACI\) Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2020-2021](#)
- [Public Health Ontario: Influenza Flu](#)



Renfrew County and District Health Unit

“Optimal Health for All in Renfrew County and District”

SHINGLES VACCINE ORDER

Return this form, by email: vaccineorders@rcdhu.com or fax: 613-735-3067

SECTION A - PLEASE PRINT:

Physician(s) Office/CHC/FHT Name - (Please order vaccine as CHC or FHT not individual HCP):

Email: _____ Name: _____

Telephone: _____ Fax: _____

IMPORTANT: PLEASE ORDER DOSES REQUIRED according to the eligibility criteria: 2 does of Shingrix vaccine is only publicly funded for seniors between 65 and 71 years of age (i.e., up to the day prior to the 72nd birthday for 2020/2021 only). If a client has already received publicly funded Zostavax, they are unable to receive publicly funded Shingrix. All wasted vaccine must be reported to the ministry of health in accordance with the vaccine storage and handling guidelines.

Shingrix is a 2-dose series and comes in packaging of 10 doses/box. Please refer to the Product Monograph for vaccine use.

SECTION B: Please order the vaccine according to criteria on the attached Information Sheet.

VACCINE	BRANDS	DOSES ON HAND	DOSES REQUIRED (10 doses/box) Minimum Order – 10 doses
Shingles Vaccine	Shingrix		

By submitting this order and signing below, I verify on behalf of the practice the following:

- Refrigerators have maintained temperatures between +2°C to +8°C and temperatures are documented twice daily
- Accurate temperature logs will be provided upon request and are kept on site until your next annual cold chain inspection
- All temperature excursions outside of +2°C to +8°C (if applicable) have been reported to RCDHU and recommendations regarding usage of the effected vaccines have been implemented.
- A contingency plan is in place should a power outage and/or cold chain incident occur, including vaccine coolers and extra temperature monitoring devices.

Date:

Signature:

*If you have any questions, please contact VPD Team at 613-732-3629 ext. 512
or via email vaccineorders@rcdhu.com*